Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19943677 | 0.81 | SYK (0.31) | SYKAURKB | |
| SCHEMBL1526113 | 0.79 | — | — | |
| SCHEMBL7366636 | 0.78 | SLC6A2 (0.30) | — | |
| SCHEMBL28329390 | 0.78 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL2200907 | 0.77 | SLC6A2 (0.33) | SYKAURKB | |
| SCHEMBL6264691 | 0.77 | — | — | |
| SCHEMBL861271 | 0.77 | — | — | |
| SCHEMBL175416 | 0.77 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL27979639 | 0.77 | — | — | |
| Ammonia Solution, Strong SCHEMBL11786318 | 0.77 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981878-B2 | Backfunctionalized imidazolinium salts and NHC carbene-metal complexes | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2021-04-20 | — | — | US | disclosed |
| US-10975038-B2 | Backfunctionalized imidazolinium salts and NHC carbene-metal complexes | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2021-04-13 | — | — | US | disclosed |
| US-10919860-B2 | Backfunctionalized imidazolinium salts and NHC carbene-metal complexes | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2021-02-16 | — | — | US | disclosed |
| US-10913723-B2 | Backfunctionalized imidazolinium salts and NHC carbene-metal complexes | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2021-02-09 | — | — | US | disclosed |
| US-20180370920-A1 | BACKFUNCTIONALIZED IMIDAZOLINIUM SALTS AND NHC CARBENE-METAL COMPLEXES | GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2018-12-27 | — | — | US | disclosed |
| US-10150738-B2 | Backfunctionalized imidazolinium salts and NHC carbene-metal complexes | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180072681-A1 | BACKFUNCTIONALIZED IMIDAZOLINIUM SALTS AND NHC CARBENE-METAL COMPLEXES | GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2018-03-15 | — | — | US | disclosed |
| US-9828347-B2 | Backfunctionalized imidazolinium salts and NHC carbene-metal complexes | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170247333-A1 | BACKFUNCTIONALIZED IMIDAZOLINIUM SALTS AND NHC CARBENE-METAL COMPLEXES | GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2017-08-31 | — | — | US | disclosed |
| US-20160102061-A1 | BACKFUNCTIONALIZED IMIDAZOLINIUM SALTS AND NHC CARBENE-METAL COMPLEXES | GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2016-04-14 | — | — | US | disclosed |
| US-4353826-A | ANTITUBERCULAR ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1982-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102061-A1 | BACKFUNCTIONALIZED IMIDAZOLINIUM SALTS AND NHC CARBENE-METAL COMPLEXES | NUDC, NBAS, NDC1 | CHRNB2 1467/4885CHRNB4 1545/4885CHRNA3 1092/4885 |
| US-20170247333-A1 | BACKFUNCTIONALIZED IMIDAZOLINIUM SALTS AND NHC CARBENE-METAL COMPLEXES | NUDC, NBAS, NDC1 | CHRNB2 1467/4885CHRNB4 1545/4885CHRNA3 1092/4885 |
| US-10975038-B2 | Backfunctionalized imidazolinium salts and NHC carbene-metal complexes | NUDC, NBAS, NDC1 | CHRNB2 1467/4885CHRNB4 1545/4885CHRNA3 1092/4885 |
| US-20180370920-A1 | BACKFUNCTIONALIZED IMIDAZOLINIUM SALTS AND NHC CARBENE-METAL COMPLEXES | NPM1, NOX3, NUDC | CHRNB2 1193/4885CHRNB4 1199/4885CHRNA3 307/4885 |
| US-10981878-B2 | Backfunctionalized imidazolinium salts and NHC carbene-metal complexes | NUDC, NBAS, NDC1 | CHRNB2 1467/4885CHRNB4 1545/4885CHRNA3 1092/4885 |
| US-10919860-B2 | Backfunctionalized imidazolinium salts and NHC carbene-metal complexes | NUDC, NBAS, NDC1 | CHRNB2 1467/4885CHRNB4 1545/4885CHRNA3 1092/4885 |
| US-20180072681-A1 | BACKFUNCTIONALIZED IMIDAZOLINIUM SALTS AND NHC CARBENE-METAL COMPLEXES | NUDC, NBAS, NDC1 | CHRNB2 1467/4885CHRNB4 1545/4885CHRNA3 1092/4885 |
| US-10913723-B2 | Backfunctionalized imidazolinium salts and NHC carbene-metal complexes | NUDC, NBAS, NDC1 | CHRNB2 1467/4885CHRNB4 1545/4885CHRNA3 1092/4885 |
| US-10150738-B2 | Backfunctionalized imidazolinium salts and NHC carbene-metal complexes | NUDC, NBAS, NDC1 | CHRNB2 1467/4885CHRNB4 1545/4885CHRNA3 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.